fda pulling tirzepatide approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA Grants Tirzepatide a New

Craig Mortensen, DC, IFMCP, QME, IFM-Certified Functional Medicine Physician and founder of Premier IFM in Placentia, CA, serving patients throughout Orange County and Southern California.

The approval makes the UK the first country to authorise an oral version of a GLP-1 weight loss treatment, a drug class already widely used in injectable form

Gut-microbiota derived bioactive metabolites and their functions in host physiology

Sites Abdomen (2 from navel) Thighs/arms Rotate to avoid irritation Needles 29-31G insulin syringes 0.5-1 mL, length Reconstitution (10 mg Vial) Add 2 mL bacteriostatic water (0.9% benzyl alcohol)